Is CT-388 Approved? Where Roche's Obesity Asset Stands Now (2026)
No. CT-388 is still a Phase 2 program. It belongs in the serious mid-stage watchlist, not in the approved-product bucket.
Current stage
Phase 2
Approval read
Not approved in the US today.
Likely window
2028 or later if the development path accelerates cleanly.
Next step
Convert Phase 2 promise into a stronger late-stage plan and prove it deserves attention in a crowded GLP-1/GIP lane.
Direct answer
No. CT-388 is still a Phase 2 program. It belongs in the serious mid-stage watchlist, not in the approved-product bucket.
Status facts for search and AI answers
What this CT-388 status page answers
Compound
CT-388
CT-388 is tracked as a GLP-1/GIP program from Roche/Carmot.
Approval read
Not approved in the US today.
No. CT-388 is still a Phase 2 program. It belongs in the serious mid-stage watchlist, not in the approved-product bucket.
Likely window
2028 or later if the development path accelerates cleanly.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Convert Phase 2 promise into a stronger late-stage plan and prove it deserves attention in a crowded GLP-1/GIP lane.
This is the milestone most likely to change the page's answer.
Decision path
What does CT-388's status mean for access?
CT-388's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- CT-388
- Stage
- Phase 2
- Approval read
- Not approved in the US today.
- Window
- 2028 or later if the development path accelerates cleanly.
Step 1
Classify availability
Phase 2 Roche/Carmot asset with real sponsor weight but less maturity than the Phase 3 leaders.
Read compound pageStep 2
Watch required milestone
Convert Phase 2 promise into a stronger late-stage plan and prove it deserves attention in a crowded GLP-1/GIP lane.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 2 Roche/Carmot asset with real sponsor weight but less maturity than the Phase 3 leaders.
CT-388 matters because Roche's scale means a mid-stage asset can become strategically important quickly if the data holds.
What needs to happen next
Convert Phase 2 promise into a stronger late-stage plan and prove it deserves attention in a crowded GLP-1/GIP lane.
What FormBlends is watching
- Whether Roche turns it into a genuine priority
- How the asset compares with VK2735 and other GLP-1/GIP names on momentum
- Whether the program's visibility rises or stalls
What could delay the timeline
- Being crowded out by better-known assets in the same lane
- Mid-stage data that is solid but not exciting enough
- Corporate prioritization risk